Seminars in Nuclear Medicine
Volume 34, Issue 3 , Pages 180-197 , July 2004

Positron emission imaging of head and neck cancer, including thyroid carcinoma

  • Heiko Schöder

      Affiliations

    • Department of Radiology/Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Henry W.D Yeung

      Affiliations

    • Department of Radiology/Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Corresponding Author InformationAddress reprint requests to Henry W.D. Yeung, MD, Department of Radiology/Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, 1275, York Avenue, New York, NY 10021 USA

References 

  1. Bohuslavizki KH, Klutmann S, Kroger S, et al.  FDG-PET detection of unknown primary tumors. J Nucl Med. 2000;41:816–822
  2. Jungehulsing M, Scheidhauer K, Damm M, et al.  2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg. 2000;123:294–301
  3. Fogarty GB, Peters LJ, Stewart J, et al.  The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. Head Neck. 2003;25:138–145
  4. Greven KM, Keyes JW, Williams DW, et al.  Occult primary tumors of the head and neck (Lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose). Cancer. 1999;86:114–118
  5. Mendenhall WM, Mancuso AA, Parsons JT, et al.  Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck. 1998;20:739–744
  6. Stokkel MP, Terhaard CH, Hordijk GJ, et al.  The detection of unknown primary tumors in patients with cervical metastases by dual-head positron emission tomography. Oral Oncol. 1999;35:390–394
  7. Regelink G, Brouwer J, de Bree R, et al.  Detection of unknown primary tumours and distant metastases in patients with cervical metastases (value of FDG-PET versus conventional modalities). Eur J Nucl Med Mol Imaging. 2002;29:1024–1030
  8. AAssar O, Fischbein NJ, Caputo GR, et al.  Metastatic head and neck cancer (role and usefulness of FDG-PET in locating occult primary tumors). Radiology. 1999;210:177–181
  9. Kole AC, Nieweg OE, Pruim J, et al.  Detection of unknown occult primary tumors using positron emission tomography. Cancer. 1998;82:1160–1166
  10. Hanasono MM, Kunda LD, Segall GM, et al.  Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope. 1999;109:880–885
  11. Braams JW, Pruim J, Kole AC, et al.  Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg. 1997;26:112–115
  12. Nieder C, Gregoire V, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma (cut down a tree to get an apple?). Int J Radiat Oncol Biol Phys. 2001;50:727–733
  13. Hannah A, Scott AM, Tochon-Danguy H, et al.  Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg. 2002;236:208–217
  14. O’Brien C, Smith J, Soong S, et al.  Neck dissection with and without radiotherapy—prognostic factors, patterns of recurrence and survival. Am J Surg. 1986;152:456–463
  15. Leemans CR, Tiwari R, Nauta JJ, et al.  Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer. 1994;73:187–190
  16. Johnson J, Barnes E, Myers E. The extracapsular spread of tumors in cervical node metastasis. Arch Otolaryngol Head Neck Surg. 1981;107:725–728
  17. Johnson JT, Myers EN, Bedetti CD, et al.  Cervical lymph node metastases. Incidence and implications of extracapsular carcinoma. Arch Otolaryngol. 1985;111:534–537
  18. Snyderman NL, Johnson JT, Schramm VL, et al.  Extracapsular spread of carcinoma in cervical lymph nodes. Impact upon survival in patients with carcinoma of the supraglottic larynx. Cancer. 1985;56:1597–1599
  19. Grandi C, Boracchi P, Mezzanotte G, et al.  Analysis of prognostic factors and proposal of a new classification for nasopharyngeal cancer. Head Neck. 1990;12:31–40
  20. Jones AS, Roland NJ, Field JK, et al.  The level of cervical lymph node metastases (their prognostic relevance and relationship with head and neck squamous carcinoma primary sites). Clin Otolaryngol. 1994;19:63–69
  21. Haddadin KJ, Soutar DS, Oliver RJ, et al.  Improved survival for patients with clinically T1/T2, N0 tongue tumors undergoing a prophylactic neck dissection. Head Neck. 1999;21:517–525
  22. van den Brekel MW, Stel HV, Castelijns JA, et al.  Cervical lymph node metastasis (Assessment of radiologic criteria). Radiology. 1990;177:379–384
  23. Curtin H, Ishwararn H, Mancuso H, et al.  Comparison of CT and MRI imaging in staging of neck metastases. Radiology. 1998;207:123–130
  24. Adams S, Baum RP, Stuckensen T, et al.  Prospective comparison of 18F-FDG-PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med. 1998;25:1255–1260
  25. Fischbein NJ, Os AA, Caputo GR, et al.  Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. AJNR Am J Neuroradiol. 1998;19:1189–1196
  26. Kao CH, Hsieh JF, Tsai SC, et al.  Comparison of 18-fluoro-2-deoxyglucose positron emission tomography and computed tomography in detection of cervical lymph node metastases of nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol. 2000;109:1130–1134
  27. Kau R, Alexiou C, Laubenbacher C, et al.  Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg. 1999;125:1322–1328
  28. Kresnik E, Mikosch P, Gallowitsch HJ, et al.  Evaluation of head and neck cancer with 18F-FDG-PET (a comparison with conventional methods). Eur J Nucl Med. 2001;28:816–821
  29. Stuckensen T, Kovacs AF, Adams S, et al.  Staging of the neck in patients with oral cavity squamous cell carcinomas (A prospective comparison of PET, ultrasound, CT and MRI). J Craniomaxillofac Surg. 2000;28:319–324
  30. Di Martino E, Nowak B, Hassan HA, et al.  Diagnosis and staging of head and neck cancer (a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings). Arch Otolaryngol Head Neck Surg. 2000;126:1457–1461
  31. Stokkel MP, ten Broek FW, Hordijk GJ, et al.  Preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emission tomography. Ann Surg. 2000;231:229–234
  32. McGuirt WF, Williams DW, Keyes JW, et al.  A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope. 1995;105:373–375
  33. Anzai Y, Piccoli CW, Outwater EK, et al.  Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging (phase III safety and efficacy study). Radiology. 2003;228:777–788
  34. Mack MG, Balzer JO, Straub R, et al.  Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology. 2002;222:239–244
  35. Stokkel MP, Moons KG, ten Broek FW, et al.  18F-fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer. Cancer. 1999;86:2370–2377
  36. Schwartz DL, Rajendran J, Yueh B, et al.  Staging of head and neck squamous cell cancer with extended-field FDG-PET. Arch Otolaryngol Head Neck Surg. 2003;129:1173–1178
  37. Schwartz LH, Ozsahin M, Zhang GN, et al.  Synchronous and metachronous head and neck carcinomas. Cancer. 1994;74:1933–1938
  38. Onizawa K, Yoshida H. Evaluation of 67 Ga citrate and 99m Tc bone scintigraphy at initial examination for primary oral squamous cell carcinoma. J Oral Maxillofac Surg. 2003;61:913–917
  39. Nilssen EL, Murthy P, McClymont L, et al.  Radiological staging of the chest and abdomen in head and neck squamous cell carcinoma—are computed tomography and ultrasound necessary?. J Laryngol Otol. 1999;113:152–154
  40. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med. 1988;29:1521–1525
  41. Rege SD, Chaiken L, Hoh CK, et al.  Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck (quantitation with PET). Radiology. 1993;189:807–812
  42. Kitagawa Y, Sadato N, Azuma H, et al.  FDG-PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. J Nucl Med. 1999;40:1132–1137
  43. Kitagawa Y, Sano K, Nishizawa S, et al.  FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging. 2003;30:63–71
  44. Kitagawa Y, Nishizawa S, Sano K, et al.  Prospective comparison of 18F-FDG-PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med. 2003;44:198–206
  45. Lowe VJ, Dunphy FR, Varvares M, et al.  Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck. 1997;19:666–674
  46. Reisser C, Haberkorn U, Dimitrakopoulou-Strauss A, et al.  Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch Otolaryngol Head Neck Surg. 1995;121:272–276
  47. Brun E, Kjellen E, Tennvall J, et al.  FDG-PET studies during treatment (Prediction of therapy outcome in head and neck squamous cell carcinoma). Head Neck. 2002;24:127–135
  48. Goerres GW, Schmid DT, Bandhauer F, et al.  Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004;130:105–109 discussion 120–121
  49. Greven KM, Williams DW, Keyes JW, et al.  Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer. 1994;74:1355–1359
  50. Greven KM, Williams DW, Keyes JW, et al.  Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer. Int J Radiat Oncol Biol Phys. 1994;29:841–845
  51. Greven KM, Williams DW, McGuirt WF, et al.  Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2001;23:942–946
  52. Goodwin WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract (When do the ends justify the means?). Laryngoscope. 2000;110:1–18
  53. van den Brekel MW. Lymph node metastases (CT and MRI). Eur J Radiol. 2000;33:230–238
  54. Anzai Y, Carroll WR, Quint DJ, et al.  Recurrence of head and neck cancer after surgery or irradiation (prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses). Radiology. 1996;2000:135–141
  55. Cordeiro P. General principles of reconstructive surgery for head and neck cancer. In:  Harrison L,  Sessions R,  Hong W editor. Head and Neck Cancer. A Multidisciplinary Approach. Philadelphia: Lippincott-Raven; 1999;p. 197–216
  56. Zlotolow I. Dental oncology and maxillofacial prosthetics. In:  Harrison L,  Sessions R,  Wong W editor. Head and Neck Cancer. A Multidisciplinary Approach. Philadelphia: Lippincott-Raven; 1995;p. 151–168
  57. Lapela M, Grenman R, Kurki T, et al.  Head and neck cancer (detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose). Radiology. 1995;197:205–211
  58. McGuirt WF, Greven KM, Keyes JW, et al.  Positron emission tomography in the evaluation of laryngeal carcinoma. Ann Otol Rhinol Laryngol. 1995;104:274–278
  59. Rege S, Maass A, Chaiken L, et al.  Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer. 1994;73:3047–3058
  60. Li P, Zhuang H, Mozley PD, et al.  Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography. Clin Nucl Med. 2001;26:131–135
  61. Stokkel MP, Terhaard CH, Hordijk GJ, et al.  The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography. Eur J Nucl Med. 1999;26:767–773
  62. McGuirt WF, Greven KM, Keyes JW, et al.  Laryngeal radionecrosis versus recurrent cancer (a clinical approach). Ann Otol Rhinol Laryngol. 1998;107:293–296
  63. Terhaard CH, Bongers V, van Rijk PP, et al.  F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/ pharyngeal cancer. Head Neck. 2001;23:933–941
  64. Lonneux M, Lawson G, Ide C, et al.  Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope. 2000;110:1493–1497
  65. Lapela M, Eigtved A, Jyrkkio S, et al.  Experience in qualitative and quantitative FDG-PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer. 2000;36:858–867
  66. Yen RF, Hung RL, Pan MH, et al.  18-fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging. Cancer. 2003;98:283–287
  67. Lowe VJ, Boyd JH, Dunphy FR, et al.  Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol. 2000;18:651–658
  68. Wong RJ, Lin DT, Schoder H, et al.  Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20:4199–4208
  69. Kunkel M, Forster GJ, Reichert TE, et al.  Detection of recurrent oral squamous cell carcinoma by [18F]-2-fluorodeoxyglucose-positron emission tomography: implications for prognosis and patient management radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Cancer. 2003;98:2257–2265
  70. Farber LA, Benard F, Machtay M, et al.  Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2–18F-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope. 1999;109:970–975
  71. Minn H, Clavo AC, Grenman R, et al.  In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med. 1995;36:252–258
  72. Haberkorn U, Strauss LG, Reisser C, et al.  Glucose uptake, perfusion, and cell proliferation in head and neck tumors (relation of positron emission tomography to flow cytometry). J Nucl Med. 1991;32:1548–1555
  73. Jacob R, Welkoborsky HJ, Mann WJ, et al.  [Fluorine-18]fluorodeoxyglucose positron emission tomography, DNA ploidy and growth fraction in squamous-cell carcinomas of the head and neck. ORL J Otorhinolaryngol Relat Spec. 2001;63:307–313
  74. Halfpenny W, Hain SF, Biassoni L, et al.  FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86:512–516
  75. Allal AS, Dulguerov P, Allaoua M, et al.  Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398–1404
  76. Bar-Shalom R, Yefremov N, Guralnik L, et al.  Clinical performance of PET/CT in evaluation of cancer (additional value for diagnostic imaging and patient management). J Nucl Med. 2003;44:1200–1209
  77. Lardinois D, Weder W, Hany TF, et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–2507
  78. Antoch G, Stattaus J, Nemat AT, et al.  Non-small cell lung cancer (Dual-modality PET/CT in preoperative staging). Radiology. 2003;229:526–533
  79. Cohade C, Osman M, Leal J, et al.  Direct comparison of (18)F-FDG-PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003;44:1797–1803
  80. Schöder H, Yeung H, Gonen M. Head and neck cancer (Clinical usefulness and accuracy of PET/CT image fusion). Radiology. 2004;231:65–72
  81. Blahd WH, Nordyke RA, Bauer FK. Radioactive iodine (I 131) in the postoperative treatment of thyroid cancer. Cancer. 1960;13:745–756
  82. Maxon HR, Thomas SR, Chen IW. The role of nuclear medicine in the treatment of hyperthyroidism and well-differentiated thyroid adenocarcinoma. Clin Nucl Med. 1981;6:P87–P98
  83. Mazzaferri EL, Young RL. Papillary thyroid carcinoma (A 10 year follow-up report of the impact of therapy in 576 patients). Am J Med. 1981;70:511–518
  84. Robbins R, Drucker W, Hann L, et al.  Advances in the detection of residual thyroid carcinoma. Adv Intern Med. 2001;46:277–294
  85. Mazzaferri EL, Robbins RJ, Spencer CA, et al.  A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433–1441
  86. Pacini F, Lippi F, Formica N, et al.  Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987;28:1888–1891
  87. Pineda JD, Lee T, Ain K, et al.  Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80:1488–1492
  88. McDougall IR. 131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma (what is being treated?). Thyroid. 1997;7:669–672
  89. Joensuu H, Ahonen A, Klemi PJ. 18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy. Eur J Nucl Med. 1988;13:502–506
  90. Dietlein M, Scheidhauer K, Voth E, et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:1342–1348
  91. Grunwald F, Kalicke T, Feine U, et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer (Results of a multicentre study). Eur J Nucl Med. 1999;26:1547–1552
  92. Grunwald F, Schomburg A, Bender H, et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1996;23:312–319
  93. Feine U, Lietzenmayer R, Hanke JP, et al.  Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468–1472
  94. Feine U, Lietzenmayer R, Hanke JP, et al.  [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I]. Nuklearmedizin. 1995;34:127–134
  95. Altenvoerde G, Lerch H, Kuwert T, et al.  Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg. 1998;383:160–163
  96. Chung JK, So Y, Lee JS, et al.  Value of FDG-PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med. 1999;40:986–992
  97. Wang W, Macapinlac H, Larson SM, et al.  [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291–2302
  98. Helal BO, Merlet P, Toubert ME, et al.  Clinical impact of (18)F-FDG-PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med. 2001;42:1464–1469
  99. Frilling A, Tecklenborg K, Gorges R, et al.  Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg. 2001;234:804–811
  100. Schluter B, Bohuslavizki KH, Beyer W, et al.  Impact of FDG-PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001;42:71–76
  101. Wang W, Larson SM, Fazzari M, et al.  Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107–1113
  102. Robbins R, Reibke R, Drucker W, et al.  Real-time prognosis in metastatic thyroid cancer based on FDG-PET scanning. Thyroid. 2003;13:701; (abstr)
  103. Haraguchi K, Rani CS, Field JB. Effects of thyrotropin, carbachol, and protein kinase-C stimulators on glucose transport and glucose oxidation by primary cultures of dog thyroid cells. Endocrinology. 1988;123:1288–1295
  104. Filetti S, Damante G, Foti D. Thyrotropin stimulates glucose transport in cultured rat thyroid cells. Endocrinology. 1987;120:2576–2581
  105. Moog F, Linke R, Manthey N, et al.  Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med. 2000;41:1989–1995
  106. Petrich T, Borner AR, Otto D, et al.  Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2002;29:641–647
  107. Plotkin M, Hautzel H, Krause BJ, et al.  Implication of 2–18fluor-2-deoxyglucose positron emission tomography in the follow-up of Hürthle cell thyroid cancer. Thyroid. 2002;12:155–161
  108. Lowe VJ, Mullan BP, Hay ID, et al.  18F-FDG-PET of patients with Hürthle cell carcinoma. J Nucl Med. 2003;44:1402–1406
  109. Brandt-Mainz K, Muller SP, Gorges R, et al.  The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med. 2000;27:490–496
  110. Diehl M, Risse JH, Brandt-Mainz K, et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer (results of a multicentre study). Eur J Nucl Med. 2001;28:1671–1676
  111. Gourgiotis L, Sarlis NJ, Reynolds JC, et al.  Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. J Clin Endocrinol Metab. 2003;88:637–641
  112. Hoegerle S, Altehoefer C, Ghanem N, et al.  18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64–71
  113. Yasuda S, Shohtsu A, Ide M, et al.  Chronic thyroiditis (Diffuse uptake of FDG at PET). Radiology. 1998;207:775–778
  114. Ramos CD, Chisin R, Yeung HW, et al.  Incidental focal thyroid uptake on FDG positron emission tomographic scans may represent a second primary tumor. Clin Nucl Med. 2001;26:193–197
  115. Wiesner W, Engel H, von Schulthess GK, et al.  FDG-PET-negative liver metastases of a malignant melanoma and FDG-PET-positive Hürthle cell tumor of the thyroid. Eur Radiol. 1999;9:975–978
  116. Cohen MS, Arslan N, Dehdashti F, et al.  Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery. 2001;130:941–946
  117. Kang KW, Kim SK, Kang HS, et al.  Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab. 2003;88:4100–4104
  118. Pentlow KS, Graham MC, Lambrecht RM, et al.  Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996;37:1557–1562
  119. Freudenberg LS, Antoch G, Gorges R, et al.  Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma (A case report). Eur Radiol. 2003;13(suppl):L19–L23
  120. Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol. 2002;37:169–174
  121. Eschmann SM, Reischl G, Bilger K, et al.  Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging. 2002;29:760–767

PII: S0001-2998(04)00022-4

doi: 10.1053/j.semnuclmed.2004.03.004

Seminars in Nuclear Medicine
Volume 34, Issue 3 , Pages 180-197 , July 2004

Article Tools

* Image Usage & Resolution